BR0312427A - Combination, use of a combination, method for producing an inhibitory effect of ibat in a warm-blooded animal, method of preventing diarrhea, pharmaceutical composition, method of treating hyperlipidemic conditions in a warm-blooded animal, and, use of a metallic salt - Google Patents

Combination, use of a combination, method for producing an inhibitory effect of ibat in a warm-blooded animal, method of preventing diarrhea, pharmaceutical composition, method of treating hyperlipidemic conditions in a warm-blooded animal, and, use of a metallic salt

Info

Publication number
BR0312427A
BR0312427A BR0312427-4A BR0312427A BR0312427A BR 0312427 A BR0312427 A BR 0312427A BR 0312427 A BR0312427 A BR 0312427A BR 0312427 A BR0312427 A BR 0312427A
Authority
BR
Brazil
Prior art keywords
combination
warm
blooded animal
ibat
pharmaceutical composition
Prior art date
Application number
BR0312427-4A
Other languages
Portuguese (pt)
Inventor
Eva-Karin Anderberg
Erik S Derlind
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0312427A publication Critical patent/BR0312427A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMBINAçãO, USO DE UMA COMBINAçãO, MéTODO PARA A PRODUçãO DE UM EFEITO INIBITóRIO DE IBAT EM UM ANIMAL DE SANGUE QUENTE, MéTODO DE PREVENçAO DE DIARRéIA, COMPOSIçãO FARMACêUTICA, MéTODO DE TRATAMENTO DE CONDIçõES HIPERLIPIDêMICAS EM UM ANIMAL DE SANGUE QUENTE, E, USO DE UM SAL METáLICO". é descrita uma combinação, que compreende um inibidor de IBAT, ou um sal farmaceuticamente aceitável, solvato de tal sal ou uma prodroga do mesmo, e um sal metálico, em que o sal metálico é formulado para ser liberado no íleo terminal, ceco e/cólon. Composições contendo esta combinação e usos da combinação são também descritas."COMBINATION, USE OF A COMBINATION, METHOD FOR THE PRODUCTION OF AN IBAT INHIBITORY EFFECT IN A HOT BLOOD ANIMAL, DIARRHEA PREVENTION METHOD, PHARMACEUTICAL COMPOSITION, METHOD OF CONDIENTAL HYDROID MEASURES OF A METAL SALT ". A combination comprising an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate of such a salt or a prodrug thereof, and a metal salt, wherein the metal salt is formulated to be released into the terminal ileum, cecum and / is described. colon. Compositions containing this combination and uses of the combination are also described.

BR0312427-4A 2002-07-13 2003-07-09 Combination, use of a combination, method for producing an inhibitory effect of ibat in a warm-blooded animal, method of preventing diarrhea, pharmaceutical composition, method of treating hyperlipidemic conditions in a warm-blooded animal, and, use of a metallic salt BR0312427A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0216321.0A GB0216321D0 (en) 2002-07-13 2002-07-13 Therapeutic treatment
PCT/GB2003/002978 WO2004006899A1 (en) 2002-07-13 2003-07-09 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea

Publications (1)

Publication Number Publication Date
BR0312427A true BR0312427A (en) 2005-04-19

Family

ID=9940407

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312427-4A BR0312427A (en) 2002-07-13 2003-07-09 Combination, use of a combination, method for producing an inhibitory effect of ibat in a warm-blooded animal, method of preventing diarrhea, pharmaceutical composition, method of treating hyperlipidemic conditions in a warm-blooded animal, and, use of a metallic salt

Country Status (20)

Country Link
US (1) US20060083790A1 (en)
EP (1) EP1539120A1 (en)
JP (1) JP2005536502A (en)
KR (1) KR20050027108A (en)
CN (1) CN1668286A (en)
AR (1) AR040553A1 (en)
AU (1) AU2003246932A1 (en)
BR (1) BR0312427A (en)
CA (1) CA2492374A1 (en)
GB (1) GB0216321D0 (en)
IL (1) IL166068A0 (en)
IS (1) IS7678A (en)
MX (1) MXPA05000461A (en)
NO (1) NO20045527L (en)
PL (1) PL374665A1 (en)
RU (1) RU2004138083A (en)
TW (1) TW200418821A (en)
UY (1) UY27890A1 (en)
WO (1) WO2004006899A1 (en)
ZA (1) ZA200500212B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
BRPI0212346B1 (en) 2001-09-08 2016-02-02 Albireo Ab COMPOUNDS DERIVED FROM BENZOTIADIAZEPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF WITH INHIBITING EFFECTS ON THE TRANSPORTATION OF ILEAL BILE ACID, PROCESS FOR THE PREPARATION OF THE SAME, USE THEREOF, AND, PHARMACEUTICAL COMPOSITION.
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
AR057828A1 (en) * 2005-09-29 2007-12-19 Astrazeneca Ab COMPOUNDS DERIVED FROM AZETIDINE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITION
CA2679314A1 (en) 2007-03-08 2008-09-12 Albireo Ab 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory conditions
RS55266B1 (en) 2010-11-08 2017-02-28 Albireo Ab Ibat inhibitors for the treatment of liver diseases
AU2011326872C1 (en) 2010-11-08 2015-02-19 Albireo Ab A pharmaceutical combination comprising an IBAT inhibitor and a bile acid binder
ES2633766T3 (en) 2011-10-28 2017-09-25 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver diseases
JO3301B1 (en) 2013-04-26 2018-09-16 Albireo Ab Crystal modifications of elobixibat
CN106659726A (en) 2014-06-25 2017-05-10 Ea制药株式会社 Solid preparation, and method for preventing or reducing discoloration thereof
KR101674806B1 (en) * 2014-10-20 2016-11-10 씨제이헬스케어 주식회사 Novel aminoalkylbenzothiazepine derivatives and use thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601744B (en) 2016-02-09 2022-01-04 阿尔比里奥公司 Oral cholestyramine formulations and uses thereof
ES2874546T3 (en) 2016-02-09 2021-11-05 Albireo Ab Oral formulation of cholestyramine and its use
KR101844184B1 (en) 2017-07-21 2018-04-02 씨제이헬스케어 주식회사 Use of an aminoalkylbenzothiazepine derivative
EP3664781A1 (en) 2017-08-09 2020-06-17 Albireo AB Cholestyramine granules, oral cholestyramine formulations and use thereof
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2019234077A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2019245449A1 (en) 2018-06-20 2019-12-26 Albireo Ab Pharmaceutical formulation of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
FI3921028T3 (en) 2019-02-06 2023-01-31 Benzothiadiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
EP3921027B1 (en) 2019-02-06 2023-07-19 Albireo AB Benzothiazepine compounds and their use as bile acid modulators
TW202134218A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothiazepine compounds and their use as bile acid modulators
AR120682A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
AR120683A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
KR20220109450A (en) 2019-12-04 2022-08-04 알비레오 에이비 Benzothia(di)azepine compounds and their use as bile acid modulators
CN114786772B (en) 2019-12-04 2024-04-09 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
TW202134223A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023537285A (en) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (en) 2020-11-12 2023-11-22 アルビレオ エービー Odevixibat for the treatment of progressive familial intrahepatic cholestasis (PFIC)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (en) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
US20230338392A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2024008766A1 (en) 2022-07-05 2024-01-11 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
SE9901387D0 (en) * 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6287609B1 (en) * 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
SE0003766D0 (en) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation

Also Published As

Publication number Publication date
IL166068A0 (en) 2006-01-15
JP2005536502A (en) 2005-12-02
RU2004138083A (en) 2005-10-10
IS7678A (en) 2005-01-28
CN1668286A (en) 2005-09-14
MXPA05000461A (en) 2005-03-23
WO2004006899A1 (en) 2004-01-22
UY27890A1 (en) 2004-02-27
CA2492374A1 (en) 2004-01-22
NO20045527L (en) 2005-04-07
GB0216321D0 (en) 2002-08-21
ZA200500212B (en) 2006-07-26
EP1539120A1 (en) 2005-06-15
KR20050027108A (en) 2005-03-17
TW200418821A (en) 2004-10-01
PL374665A1 (en) 2005-10-31
AU2003246932A1 (en) 2004-02-02
US20060083790A1 (en) 2006-04-20
AR040553A1 (en) 2005-04-13

Similar Documents

Publication Publication Date Title
BR0312427A (en) Combination, use of a combination, method for producing an inhibitory effect of ibat in a warm-blooded animal, method of preventing diarrhea, pharmaceutical composition, method of treating hyperlipidemic conditions in a warm-blooded animal, and, use of a metallic salt
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
MY132106A (en) New pyridazin-3(2h)-one derivatives
BR0112160A (en) Glucocorticoid Selective Anti-Inflammatory Agents
LU91751I2 (en) Asenapin and its pharmaceutically acceptable derivatives (SYCREST®)
AU3664401A (en) Platelet adp receptor inhibitors
PT1465626E (en) Pharmaceutical compositions (kit) comprising dihydropyridinone compounds and an immunoregulatory (or an antiinflammatory) agent and their uses
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
BR9811099A (en) Urokinase inhibitors
UA48946C2 (en) Arylalkyldiazinones, method for their preparation, pharmaceutical composition, method of its preparation and treatment method
EE05423B1 (en) Use of an IL-18 inhibitor for the manufacture of a medicament for the treatment or prevention of liver injury and other diseases, the use of a vector and a cell in the manufacture of an inhibitor, and a pharmaceutical composition comprising an IL-18 inhibitor.
EP1673078A4 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
UA39166C2 (en) derivatives of N-hydroxyurea AS inhibitors of lipoxygenase by mammals, method for the preparation thereof and method for inhibiting lipoxygenase by mammals
GEP20094675B (en) Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain
TW200514772A (en) Novel tetrahydropyridine derivatives
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
MXPA04003611A (en) Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases.
AP9801202A0 (en) Atropisomers of 3-heteroaryl-4(3H)-quinazolinones.
MX9709451A (en) Benzisoxazole and indazole derivatives as antipsychotic agents.
PT1206444E (en) COMPOUNDS THAT INHIBIT TRIPTASE ACTIVITY
MXPA02004441A (en) Isoxazole derivatives to be used as phosphodiesterase vii inhibitors.
SI1474174T1 (en) Composition for oral or rectal administration
NZ287551A (en) N-hydroxyureas that inhibit the 5-lipoxygenase enzyme as anti-inflammatory agents

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]